This Listing of Claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS

1. ***(currently** amended):* A method for producing a population of mononuclear cells overexpressing IL-10 polypeptide which cells (i) are not selected on the basis of specificity for a predetermined antigen and (ii) treat an inflammatory disease or condition in an antigen-independent manner, the method comprising:

~~(a) providing mammalian peripheral blood mononuclear cells wherein, if the cells comprise lymphocytes, the lymphocytes are not selected or enriched on the basis of their antigen specificity;~~

(a[[b]]) modifying ~~introducing into~~ at least a portion ~~fraction~~ of a mammalian peripheral blood ~~said~~ mononuclear cell[[s]] population,

among which cells lymphocytes are not selected or enriched on the basis of antigen specificity,

by introducing into said cells an expression construct that comprises a nucleotide sequence encoding an IL-10 polypeptide; and,

(b[[c]]) recovering, from said modified mononuclear cells, cells that

(i) overexpress the IL-10 polypeptide, and

(ii) are not specific for a predetermined antigen,

thereby producing said population of mononuclear cells overexpressing IL-10 that are capable of treating said inflammatory disease.

2. ***(currently** amended):* A method according to claim 1, wherein the expression construct is introduced into an enriched fraction or subset of said peripheral blood mononuclear cell[[s]] population ~~are provided~~.

3. ***(currently** amended):* A method according to claim 2, wherein the enriched fraction or subset is selected from the group consisting of (i) lymphocytes ~~or a subset thereof~~, (ii) macrophages, (iii) monocytes [[or]] and (iv) dendritic cells ~~(DC)~~.

4. ***(currently** amended):* A method according to claim 1, wherein prior to the introducing step (a[[b]]), the mononuclear cells are induced to, or allowed to, proliferate.

5. *(previously presented):* A method according to claim 4, wherein the mononuclear cells are induced to proliferate by a proliferating agent.

6. *(previously presented):* A method according to claim 5, wherein the proliferating agent is one or more of

(a) an anti-CD3 antibody;

(b) an anti-CD28 antibody; or

(c) phytohemagglutinin.

7. ***(currently** amended):* A method according to claim 1, wherein subsequent to step (a[[b]]), the modified mononuclear cells are fractionated to yield an enriched cell [[a]] fraction or subset ~~thereof~~.

8. *(previously presented):* A method according to claim 7, wherein the fraction or subset comprises enriched

(i) lymphocytes or a subset thereof,

(ii) macrophages or monocytes, or

(iii) dendritic cells.

9. ***(currently** amended):* A method according to claim 1, wherein subsequent to step (a[[b]]), the modified mononuclear cells are enriched for cells that overexpress the IL-10-encoding nucleotide sequence.

10. *(withdrawn):* A method for producing a pharmaceutical composition comprising mononuclear cells overexpressing IL-10, which method comprises

(a) producing the mononuclear cells overexpressing IL-10 in accordance with claim 1, and

(b) combining said cells with an acceptable pharmaceutical carrier.

11. *(withdrawn; currently amended)::* A composition comprising mononuclear cells that are not selected to be specific for a predetermined antigen which cells are modified to ~~that~~ comprise an IL-10 transgene.

12. *(withdrawn; currently amended):* A T lymphocyte composition that is a fraction of the mononuclear cells according to claim 11, ~~wherein the mononuclear cells comprise~~ which T cells ~~that~~ comprise said IL-10 transgene.

13. *(withdrawn; currently amended):* A T lymphocyte composition according to claim 12, wherein the T cells functionally mimic regulatory T cells in that they inhibit:

(a) proliferation of autologous responder cells, and/or

(b) production of pro-inflammatory cytokine IL-12 by dendritic cells.

14. *(withdrawn):* A pharmaceutical composition comprising the composition according to claim 11, and a pharmaceutically acceptable carrier.

15. *(withdrawn):* A method of treating a disease or condition associated with undesired activation and/or expansion of T cells, which method comprises administering an effective amount of a pharmaceutical composition according to claim 14 to a subject suffering from said disease or condition.

16. *(withdrawn):* A method according to claim 15, wherein the disease or condition is a Th1-mediated disease or condition.

17. *(withdrawn):* A method according to claim 16, wherein the Th1-mediated disease or condition is Crohn's disease, reactive arthritis, insulin-dependent diabetes, colitis, pancreatitis, an inflammatory lung disease, an inflammatory eye disease, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, chronic articular rheumatism, contact dermatitis, psoriasis, graft rejection, graft-versus-host disease, or sarcoidosis.

18. to 19. (canceled)

20. *(**currently** amended)* A method according to claim 3 wherein the enriched lymphocyte subset comprises an enriched population of B lymphocytes ~~cells~~, T lymphocytes ~~cells~~ or CD4+ lymphocytes ~~cells~~.

21. *(**currently** amended)* A method according to claim 8 wherein the enriched lymphocyte[[s]] subset comprises an enriched population of B lymphocytes ~~cells~~, T lymphocytes ~~cells~~ or CD4+ lymphocytes ~~cells~~.

22. (canceled)

23. *(withdrawn)* A method according to claim 16 wherein the Th1-mediated disease is an inflammatory disease.